CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Report for D009461: Neurologic Manifestations NIH

(Synonyms: Neurologic Manifestations)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug786 Observational study only Wiki 0.58

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D000066553 Problem Behavior NIH 0.41
D004194 Disease NIH 0.26
D001523 Mental Disorders NIH 0.24
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0000708 Behavioral abnormality HPO 0.41

There are 3 clinical trials

Clinical Trials

1 Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders: An Observational Study of the Covid-19 Neurological and Psychiatric Manifestations

Covid-19 pandemic now affects more than two million people worldwide. The neurotropism of the virus is assumed by its frequent association with neurological symptoms (anosmia, ageusia, headaches) but the extent of the central or peripheral nervous system involvement and the associated symptomatology remain poorly known for now. The main objective of this study is to describe the neurological and psychiatric manifestations occurring in the context of Covid-19 infection in patients hospitalized or followed-up in the APHP.SU hospital group. A better understanding of the neuropsychiatric impairment related to Covid-19 would improve the management of these patients in the acute phase, and knowledge of subsequent complications would allow adapting their rehabilitation and follow-up. The precise phenomenological description of these manifestations and the imaging, biology and neuropathology data will be compiled from the data collected by the physicians in charge of these patients as part of their inpatient or outpatient care. This study will also allow collecting unusual clinical manifestations from patients followed for neurological or psychiatric pathology in hospital departments and presenting a Covid-19 infection, in order to optimize the reorganization of their management, follow-up and rehabilitation in the epidemic context.

NCT04362930 Neurologic Manifestations Psychiatric Disorders COVID-19
MeSH:Neurologic Manifestations Disease Mental Disorders Problem Behavior
HPO:Behavioral abnormality

Primary Outcomes

Description: Frequency of central or peripheral neurological or psychiatric symptoms observed in patients with COVID-19

Measure: Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19

Time: 12 months

Secondary Outcomes

Description: Impact on neurological or psychiatric disease trajectories assessed by severity scores or subjective progression (improved, stable, impaired) during and after COVID-19 pathology in patients with pre-existing neurological and psychiatric diseases

Measure: Progression of pre-existing neurological or psychiatric pathologies

Time: 12 months

2 Neurologic Manifestations of COVID 19 in Children

This is a multicenter, multinational observational cohort study to document neurologic manifestations of COVID 19 among pediatric patients requiring hospital admission for confirmed or suspected COVID 19 (Coronavirus 19 disease, caused by infection with the SARS-CoV-2 (acute respiratory syndrome 2 ) virus. SARS-CoV2 shares significant structural and biological similarities with SARS-CoV including using the ACE-2 receptor as a docking site, a property that confers neurotropism. This study is sponsored and led by members of the Pediatric Neurocritical Care Research Group (PNCRG).

NCT04379089 COVID Neurologic Manifestations Other: Observational study only
MeSH:Neurologic Manifestations

Primary Outcomes

Description: Chart review

Measure: Frequency of neurologic manifestations of COVID 19 among pediatric patients requiring hospital admission for confirmed or presumed COVID 19

Time: From date of hospital admission until the date of hospital discharge (including death), assessed up to 12 months

Secondary Outcomes

Description: Chart Review

Measure: Associations between prescription of empiric COVID-19 directed therapies and patient characteristics and outcomes among children with or without neurologic manifestations and confirmed or presumed COVID-19

Time: From date of hospital admission until the date of hospital discharge (including death), assessed up to 12 months

3 COVID-19 Outcomes: A Retrospective Study of Neurological Manifestations and Associated Symptoms (The Philippine CORONA Study)

This study will determine the neurological profile and predictors of outcomes in patients with COVID-19 disease in the Philippines. It will also evaluate if there is significant difference between COVID-19 patients with neurological manifestations compared to those COVID-19 patients without neurological manifestations in terms of various prespecified clinical outcomes. Furthermore, the likelihood of these outcomes in COVID-19 patients with neurological manifestations compared to those without neurological manifestation will be determined in this study.

NCT04386083 Coronavirus Disease 2019
MeSH:Coronavirus Infections Neurologic Manifestations

Primary Outcomes

Description: Defined as patients with confirmed COVID-19 who died

Measure: Mortality (binary outcome)

Time: from admission until occurrence of mortality, assessed up to 6 months

Description: Defined as the patient with confirmed COVID-19 who experienced clinical symptoms and signs of respiratory insufficiency. Clinically, this condition may manifest as tachypnea, abnormal blood gases (hypoxemia or hypercapnia), signs of increased work of breathing, and requires oxygen supplementation

Measure: Respiratory failure (binary outcome)

Time: from admission until occurrence of respiratory failure, assessed up to 6 months

Secondary Outcomes

Description: Defined as the number of days from initiation of assisted ventilation to extubation

Measure: Duration of ventilator dependence (continuous outcome)

Time: day of intubation to day of extubation, assessed up to 6 months

Description: Defined as the patients with confirmed COVID-19 who are admitted to an ICU or ICU-comparable setting

Measure: Intensive care unit (ICU) admission (binary outcome)

Time: admission to ICU admission, assessed up to 6 months

Other Outcomes

Description: Defined as the number of days admitted in the ICU or ICU-comparable setting

Measure: Length of ICU stay (continuous outcome)

Time: ICU admission to ICU discharge, assessed up to 6 months

Description: Defined as the number of days from admission to discharge

Measure: Length of hospital stay (continuous outcome)

Time: admission to hospital discharge, assessed up to 6 months

HPO Nodes